Notice: This company has been marked as potentially delisted and may not be actively trading. Prometheus Biosciences (RXDX) News Today Add Compare Share Share Headlines Stock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period EQS-News: Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to AbivaxNovember 14, 2024 | markets.businessinsider.comAbivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to AbivaxNovember 14, 2024 | markets.businessinsider.comCormorant Private Healthcare Fund III LP's Net WorthMarch 6, 2024 | benzinga.comHarbor Capital Advisors Inc. Takes $225,000 Position in Prometheus Biosciences, Inc. (NASDAQ:RXDX)Harbor Capital Advisors Inc. bought a new stake in Prometheus Biosciences, Inc. (NASDAQ:RXDX - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 2,099 shares of the biopharmaceutical company's sJuly 13, 2023 | marketbeat.comPrometheus Biosciences, Inc. (NASDAQ:RXDX) Receives Consensus Recommendation of "Hold" from AnalystsPrometheus Biosciences, Inc. (NASDAQ:RXDX - Get Free Report) has been given a consensus rating of "Hold" by the eleven research firms that are currently covering the company, MarketBeat reports. Seven research analysts have rated the stock with a hold recommendation and four have issued a buy recoJuly 11, 2023 | marketbeat.comVictory Capital Management Inc. Boosts Holdings in Prometheus Biosciences, Inc. (NASDAQ:RXDX)Victory Capital Management Inc. boosted its position in shares of Prometheus Biosciences, Inc. (NASDAQ:RXDX - Get Rating) by 1,359.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 118,407 shares of the biopharmaceutJune 24, 2023 | marketbeat.comWaypoint Capital Advisors LLC Sells 16,715 Shares of Prometheus Biosciences, Inc. (NASDAQ:RXDX)Waypoint Capital Advisors LLC lessened its position in Prometheus Biosciences, Inc. (NASDAQ:RXDX - Get Rating) by 9.8% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 154,466 shares of the biopharmaceuticJune 23, 2023 | marketbeat.comTrading was temporarily halted for "RXDX" at 07:06 PM with a stated reason of "News pending."June 16, 2023 | marketbeat.comPrometheus Biosciences, Inc. (NASDAQ:RXDX) Receives Average Rating of "Hold" from AnalystsShares of Prometheus Biosciences, Inc. (NASDAQ:RXDX - Get Rating) have earned an average rating of "Hold" from the eleven analysts that are currently covering the firm, MarketBeat reports. Seven analysts have rated the stock with a hold recommendation and four have issued a buy recommendation onJune 16, 2023 | marketbeat.comFred Alger Management LLC Purchases 323,091 Shares of Prometheus Biosciences, Inc. (NASDAQ:RXDX)Fred Alger Management LLC increased its position in Prometheus Biosciences, Inc. (NASDAQ:RXDX - Get Rating) by 31.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,359,256 shares of the biopharmaceutical company's stocJune 14, 2023 | marketbeat.comMoran Wealth Management LLC Purchases New Holdings in Prometheus Biosciences, Inc. (NASDAQ:RXDX)Moran Wealth Management LLC acquired a new stake in Prometheus Biosciences, Inc. (NASDAQ:RXDX - Get Rating) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 5,292 shares of the biopharmaceutical company's stock,June 11, 2023 | marketbeat.comDriehaus Capital Management LLC Takes Position in Prometheus Biosciences, Inc. (NASDAQ:RXDX)Driehaus Capital Management LLC acquired a new stake in shares of Prometheus Biosciences, Inc. (NASDAQ:RXDX - Get Rating) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 271,07June 9, 2023 | marketbeat.comPlatinum Investment Management Ltd. Lowers Stock Position in Prometheus Biosciences, Inc. (NASDAQ:RXDX)Platinum Investment Management Ltd. lowered its position in Prometheus Biosciences, Inc. (NASDAQ:RXDX - Get Rating) by 24.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 265,791 shares of the biopharmaceutical companyJune 8, 2023 | marketbeat.comAmerican International Group Inc. Purchases 1,925 Shares of Prometheus Biosciences, Inc. (NASDAQ:RXDX)American International Group Inc. lifted its position in shares of Prometheus Biosciences, Inc. (NASDAQ:RXDX - Get Rating) by 13.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 16,459 shares of the biJune 7, 2023 | marketbeat.comPrometheus Biosciences, Inc. (NASDAQ:RXDX) Position Increased by Principal Financial Group Inc.Principal Financial Group Inc. increased its stake in Prometheus Biosciences, Inc. (NASDAQ:RXDX - Get Rating) by 15.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 10,309 shares of the biopharmaceutical coJune 4, 2023 | marketbeat.comUBS Group AG Buys 31,951 Shares of Prometheus Biosciences, Inc. (NASDAQ:RXDX)UBS Group AG lifted its stake in shares of Prometheus Biosciences, Inc. (NASDAQ:RXDX - Get Rating) by 1,679.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 33,854 shares of the biopharmaceutical cMay 31, 2023 | marketbeat.comPrometheus Biosciences: 8.5% IRR And Closing In A MonthMay 30, 2023 | seekingalpha.comPrometheus Biosciences (NASDAQ: RXDX)May 28, 2023 | fool.comEnvestnet Asset Management Inc. Acquires 3,175 Shares of Prometheus Biosciences, Inc. (NASDAQ:RXDX)Envestnet Asset Management Inc. boosted its holdings in Prometheus Biosciences, Inc. (NASDAQ:RXDX - Get Rating) by 54.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,982 shares of the biopharmaceuticMay 26, 2023 | marketbeat.comFirst Trust Advisors LP Acquires 26,916 Shares of Prometheus Biosciences, Inc. (NASDAQ:RXDX)First Trust Advisors LP boosted its position in Prometheus Biosciences, Inc. (NASDAQ:RXDX - Get Rating) by 30.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 116,534 shares of the biopharmaceutical compaMay 24, 2023 | marketbeat.comPrometheus Biosciences gains after HSR waiting for sale to Merck expiresMay 23, 2023 | msn.comSHAREHOLDER ALERT: Weiss Law Investigates Prometheus Biosciences, Inc.May 23, 2023 | barrons.comSectoral Asset Management Inc. Purchases 9,000 Shares of Prometheus Biosciences, Inc. (NASDAQ:RXDX)Sectoral Asset Management Inc. boosted its stake in Prometheus Biosciences, Inc. (NASDAQ:RXDX - Get Rating) by 8.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 112,210 shares of the biopharMay 22, 2023 | marketbeat.comPrometheus Biosciences, Inc. (NASDAQ:RXDX) Receives Consensus Rating of "Hold" from BrokeragesPrometheus Biosciences, Inc. (NASDAQ:RXDX - Get Rating) has received an average rating of "Hold" from the eleven research firms that are currently covering the firm, Marketbeat.com reports. Seven analysts have rated the stock with a hold recommendation and four have given a buy recommendation to tMay 22, 2023 | marketbeat.comWhat Makes Prometheus Biosciences (RXDX) an Attractive Investment Choice?May 18, 2023 | finance.yahoo.comJennison Associates LLC Purchases New Position in Prometheus Biosciences, Inc. (NASDAQ:RXDX)Jennison Associates LLC bought a new position in Prometheus Biosciences, Inc. (NASDAQ:RXDX - Get Rating) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund bought 122,438 shares of the biopharmaceutical company's stock, valued at approximately $13,4May 17, 2023 | marketbeat.comState Board of Administration of Florida Retirement System Reduces Stake in Prometheus Biosciences, Inc. (NASDAQ:RXDX)State Board of Administration of Florida Retirement System lowered its position in Prometheus Biosciences, Inc. (NASDAQ:RXDX - Get Rating) by 8.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 10,174 sMay 16, 2023 | marketbeat.comPrometheus Biosciences, Inc. (RXDX) is a Great Momentum Stock: Should You Buy?May 12, 2023 | finance.yahoo.comJefferies Downgrades Prometheus Biosciences (RXDX)May 11, 2023 | msn.comRBC Capital Maintains Prometheus Biosciences (RXDX) Sector Perform RecommendationMay 11, 2023 | msn.comPrometheus Biosciences (NASDAQ:RXDX) Stock Rating Lowered by Jefferies Financial GroupJefferies Financial Group downgraded shares of Prometheus Biosciences from a "buy" rating to a "hold" rating and raised their price objective for the stock from $160.00 to $200.00 in a research report on Wednesday.May 10, 2023 | marketbeat.comPrometheus Biosciences Reports First Quarter 2023 Financial Results and Highlights Recent Corporate ProgressMay 9, 2023 | yahoo.comAbbvie, Bristol Myers competed with Merck in sale of Prometheus - reportMay 1, 2023 | msn.comWith 67% ownership, Prometheus Biosciences, Inc. (NASDAQ:RXDX) boasts of strong institutional backingApril 29, 2023 | finance.yahoo.comIeq Capital LLC Cuts Stock Position in Prometheus Biosciences, Inc. (NASDAQ:RXDX)Ieq Capital LLC cut its holdings in shares of Prometheus Biosciences, Inc. (NASDAQ:RXDX - Get Rating) by 35.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 10,000 shares of the biopharmaceutical company's stApril 28, 2023 | marketbeat.comSG Americas Securities LLC Boosts Stake in Prometheus Biosciences, Inc. (NASDAQ:RXDX)SG Americas Securities LLC lifted its stake in shares of Prometheus Biosciences, Inc. (NASDAQ:RXDX - Get Rating) by 84.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 12,107 shares of the biopharmaceutical cApril 27, 2023 | marketbeat.comPrometheus Biosciences, Inc. (NASDAQ:RXDX) Given Consensus Rating of "Hold" by BrokeragesShares of Prometheus Biosciences, Inc. (NASDAQ:RXDX - Get Rating) have been given an average recommendation of "Hold" by the ten research firms that are currently covering the stock, MarketBeat Ratings reports. Six investment analysts have rated the stock with a hold rating and four have given a buApril 27, 2023 | marketbeat.comNew York State Common Retirement Fund Lowers Stock Holdings in Prometheus Biosciences, Inc. (NASDAQ:RXDX)New York State Common Retirement Fund lessened its stake in Prometheus Biosciences, Inc. (NASDAQ:RXDX - Get Rating) by 13.5% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 36,993 shares of the biopharmaceutical company'sApril 25, 2023 | marketbeat.comPharma Stock Roundup: JNJ Beats on Q1 Earnings, MRK to Buy RXDX & Other UpdatesApril 21, 2023 | finance.yahoo.comStrs Ohio Sells 4,700 Shares of Prometheus Biosciences, Inc. (NASDAQ:RXDX)Strs Ohio trimmed its position in shares of Prometheus Biosciences, Inc. (NASDAQ:RXDX - Get Rating) by 63.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,700 shares of the biopharmaceutical company'sApril 21, 2023 | marketbeat.comWhy Prometheus Biosciences Stock Is Skyrocketing This WeekApril 20, 2023 | finance.yahoo.comRBC Capital downgrades Prometheus Biosciences (RXDX) to a HoldApril 18, 2023 | markets.businessinsider.comPrometheus Biosciences, Inc. (RXDX) Stock Jumps 69.7%: Will It Continue to Soar?April 18, 2023 | finance.yahoo.comHow to Tell Biotech’s Likely Winners From LosersApril 18, 2023 | finance.yahoo.comLooking At Prometheus Biosciences's Recent Unusual Options ActivityApril 17, 2023 | benzinga.comSHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Prometheus Biosciences, Inc. (RXDX)April 17, 2023 | markets.businessinsider.comPrometheus (RXDX) Stock Surges 70% on Buyout Offer From MerckApril 17, 2023 | finance.yahoo.comMerck’s Deal for Prometheus Expected to Generate Billions in Additional SalesApril 17, 2023 | barrons.comMerck Acquires Prometheus Biosciences for $10.8 BillionApril 17, 2023 | msn.comMerck/Prometheus: Big Pharma must swallow bigger premiumsApril 17, 2023 | finance.yahoo.com Get Prometheus Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for RXDX and its competitors with MarketBeat's FREE daily newsletter. Email Address What Comes Next Could Be a Once-in-a-Lifetime Opportunity (Ad)A wave of technological and financial transformation is reshaping the investment landscape. For those who understand the shifts ahead, this could be the foundation for long-term wealth creation. In this exclusive briefing, I'll show you exactly how to prepare for the challenges and opportunities ahead. You'll learn actionable strategies to protect your portfolio and position yourself for growth in the months and years to come. Click here now to watch the full briefing and discover the steps to take today. RXDX Media Mentions By Week RXDX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RXDX News Sentiment▼0.770.48▲Average Medical News Sentiment RXDX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RXDX Articles This Week▼00▲RXDX Articles Average Week Get Prometheus Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for RXDX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies LIAN News PHXM News DRTSW News BCTXW News EFTRW News FBIOP News GOVXW News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RXDX) was last updated on 11/22/2024 by MarketBeat.com Staff From Our Partners[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | SponsoredCentral Bank Abandons USDYou know what doesn't care about elections? Gold. If you want to protect your savings & retirement from our...Desko Digital | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredWhat Comes Next Could Be a Once-in-a-Lifetime OpportunityA wave of technological and financial transformation is reshaping the investment landscape. For those who unde...InvestorPlace | SponsoredAre Your Retirement Savings Really Safe?What They Don’t Want You to Know About Your 401(k)The 2008-2010 crisis wiped out almost 50% of the value of retirement funds. If you knew it was coming, wouldn'...American Hartford Gold | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prometheus Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Prometheus Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
